Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050551 | 0.93 | PRKCA (0.42) | PRKCA | |
| SCHEMBL3757701 | 0.86 | PRKCA (0.42) | PRKCA | |
| SCHEMBL1828759 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL17728710 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL16359714 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL18651098 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL9862817 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL17728712 | 0.84 | PRKCA (0.42) | PRKCA | |
| SCHEMBL1639936 | 0.80 | PRKCA (0.44) | PRKCA | |
| SCHEMBL1396438 | 0.80 | PRKCA (0.44) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | PRKCA 490/4885ELANE 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.